Toby Maher
Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California · Stanford Health Care
Credentials: · · ·
History
- Present
- 1998–2000
Pulmonary Disease
- 1994–1998
University of Southampton Medical School, UK — BM — — Medicine
- 1995–1998
University of Southampton Medical School
Research
American Journal of Respiratory and Critical Care Medicine · 2022 · 2,358 citations
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
New England Journal of Medicine · 2019 · 1,188 citations
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Review · American Journal of Respiratory and Critical Care Medicine · 2016 · 1,144 citations
- JO
42 papers
41 papers
39 papers
24 papers
22 papers
22 papers
22 papers
22 papers
Grants
- 2025–2027
National Institute on Aging · UG3
PI · $943.3K · University of Southern California
Clinical trials
- 2020–2022
LYT-100 in Post-acute COVID-19 Respiratory Disease
Principal investigator · Terminated · Phase 2
PureTech
- 2019–2023
Principal investigator · Completed · Phase 2
Galecto Biotech AB
- 2026–2027
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Site PI · Recruiting · Phase 2
Rein Therapeutics
- 2025–2031
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Site PI · Recruiting · Phase 2
Avalyn Pharma Inc.